Can the HPV vaccine protect transplant patients? new study investigates
NCT ID NCT05557370
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the HPV9 vaccine (Gardasil 9) works in people who have had a kidney transplant. Researchers will measure antibody levels in 30 transplant recipients over 24 months and compare them to published data from healthy individuals. The goal is to see if the vaccine provides similar protection against HPV in this vulnerable group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert Lutheran Memorial Hospital
Milwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new graft keep dialysis access working longer?
- Can a common gout pill shield hearts in kidney disease?
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Could the choice of anesthesia quiet the Body's surgical stress response?